Medtronic, Inc. MDT today
announced findings from a new clinical analysis of the pivotal REVERSE
(Resynchronization Reverse Remodeling in Systolic Left Ventricular
Dysfunction) trial, which demonstrated that its cardiac resynchronization
therapy (CRT) devices are associated with low mortality and heart failure
hospitalization rates over 5 years, post-implant. This is the first - and
longest - study of its kind to show that CRT results in significant structural
changes to the heart in patients with mild disease (at 2 years following
implant), and also had positive, enduring long-term effects. The 5-year data
was presented today at the European Society of Cardiology's ESC Congress 2012
in Munich.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in